Abstract

One of the requirements of endodontic material is to have good biocompatibility of pulp tissue that has direct contact with the material, to promote the process of tissue repair. Reversible pulpitis needs direct pulp capping treatment with medicament materials i.e. RMGIC (Resin-Modified Glass Ionomer Cement) and MTA (Mineral Trioxide Aggregate) which are used as the gold standard for direct pulp capping treatment. Both of the materials have several disadvantages including the necrotic tissue in the area has direct contact with the pulp so that it affects the successful treatment results. Nowadays, the new materials are being developed which are expected to improve the existing material deficiencies. In this study, fibroin was extracted from Bombyx mori L. cocoon. This study aimed to examine the biocompatibility of fibroin as a new pulp capping material with RMGIC (Fuji II LC, GC, Japan) and MTA (Rootdent, Technodent, Russia). An experimental study was conducted using extracted human primary dental pulp cells in vitro through orthodontic treatment. A methyl thiazole tetrazolium (MTT) assay was employed to test biocompatibility using ELISA Reader 590 nm wavelengths for 24, 48, and 72 h, respectively. The findings showed that the biocompatibility of fibroin had the highest value of all. In conclusion, fibroin biocompatibility toward MTA and RMGIC as pulp capping materials can be aligned, however, there were no significant differences.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.